Trial Shows Rentosertib Drug May Lower Biological Age in Lung Disease Patients
In a recent study published in Nature Biotechnology, researchers from Insilico Medicine explored the effects of rentosertib, a drug designed using generative AI, on biological age markers in patients suffering from idiopathic pulmonary fibrosis, a progressive lung disease. Blood samples from 42 participants in a phase 2a trial were analyzed using six independently developed aging clocks, all of which indicated that patients treated with rentosertib appeared biologically younger than those receiving a placebo. Alex Zhavoronkov, PhD, co-CEO of Insilico Medicine, emphasized the potential significance of this finding, suggesting that if the drug could extend healthy lifespan, it could lead to substantial economic benefits.
The analysis involved a secondary review of data from a larger trial, where 71 patients were initially enrolled, and 42 consented to undergo proteomic profiling at various intervals. The researchers measured 2,841 proteins and compared the results against a reference population from the UK Biobank. Notably, the most pronounced effects were observed at the four-week mark in the group receiving 30 mg of rentosertib twice daily, where biological age appeared to be reduced by 2.7 to 3.5 years. Insilico's summary suggested that some clocks indicated reductions of up to six years, although this figure represents the upper limit rather than a central tendency.
However, the authors cautioned that the study does not definitively separate the effects of rentosertib on aging from its impact on lung function, as idiopathic pulmonary fibrosis itself can influence blood protein levels. They noted that while the treated group showed a reversal of age-associated protein patterns, the placebo group continued along a normal aging trajectory, suggesting a potential effect of the drug.
The primary goal of the original trial was safety, and while adverse events were reported at similar rates across all groups, the efficacy of rentosertib in improving lung function will be further evaluated in an upcoming phase 3 trial. The researchers also deposited their proteomic data with the China National Center for Bioinformation and made their analysis methods available as open-source software, allowing for independent verification of their findings. While the concept of biological age as measured by proteomic clocks is gaining traction, it is important to note that regulatory agencies do not currently recognize changes in biological age as a valid endpoint for drug approval.
Overall, while the findings present intriguing possibilities for the relationship between lung health and biological aging, the modest sample size and the nature of the study underscore the need for further investigation to establish the broader applicability of these results.




